Lineage Cell Therapeutics FY2029 EPS Cut by B. Riley

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) - Investment analysts at B. Riley decreased their FY2029 earnings estimates for shares of Lineage Cell Therapeutics in a research note issued to investors on Friday, May 23rd. B. Riley analyst M. Mamtani now anticipates that the company will post earnings per share of $0.16 for the year, down from their previous forecast of $0.20. B. Riley currently has a "Buy" rating and a $3.00 target price on the stock. The consensus estimate for Lineage Cell Therapeutics' current full-year earnings is ($0.12) per share.

Several other research firms also recently commented on LCTX. HC Wainwright reaffirmed a "buy" rating and issued a $9.00 price objective on shares of Lineage Cell Therapeutics in a report on Tuesday, March 11th. D. Boral Capital reaffirmed a "buy" rating and issued a $2.00 price objective on shares of Lineage Cell Therapeutics in a report on Tuesday, March 11th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $4.20.

Lineage Cell Therapeutics Trading Down 0.5%

Shares of LCTX stock traded down $0.00 during trading hours on Monday, hitting $0.65. 517,706 shares of the company were exchanged, compared to its average volume of 1,527,329. The firm has a fifty day simple moving average of $0.48 and a 200 day simple moving average of $0.62. Lineage Cell Therapeutics has a 52-week low of $0.37 and a 52-week high of $1.15. The stock has a market capitalization of $143.05 million, a price-to-earnings ratio of -5.41 and a beta of 1.21.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Fort Sheridan Advisors LLC boosted its holdings in Lineage Cell Therapeutics by 71.5% in the 4th quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company's stock valued at $28,000 after purchasing an additional 23,000 shares during the period. Atria Wealth Solutions Inc. bought a new stake in shares of Lineage Cell Therapeutics during the 4th quarter worth $29,000. HighTower Advisors LLC lifted its holdings in shares of Lineage Cell Therapeutics by 49.5% during the 4th quarter. HighTower Advisors LLC now owns 57,706 shares of the company's stock worth $29,000 after acquiring an additional 19,100 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of Lineage Cell Therapeutics by 35.5% during the 4th quarter. SG Americas Securities LLC now owns 68,973 shares of the company's stock worth $35,000 after acquiring an additional 18,053 shares during the last quarter. Finally, Two Sigma Advisers LP lifted its holdings in shares of Lineage Cell Therapeutics by 312.2% during the 4th quarter. Two Sigma Advisers LP now owns 86,964 shares of the company's stock worth $44,000 after acquiring an additional 65,864 shares during the last quarter. 62.47% of the stock is owned by institutional investors.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.